Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps Latest publication
Casirivimab
Emergency use authorization Experimental Antiviral Jan/23/2023
Imdevimab
Emergency use authorization Experimental Antiviral Jan/23/2023
T cells
Potential treatment - pre-clinical evidence Used to treat other disease Antiviral Jan/18/2023
Remdesivir
Approved by FDA Experimental Antiviral Jan/18/2023
Mesenchymal stem cells
Potential treatment - clinical evidence Experimental Other treatment Oct/17/2022
Anti-spike nanobody-IFN-β conjugated exosomes
Potential treatment - pre-clinical evidence Experimental Antiviral Sep/26/2022
IMAT-MSCs
Potential treatment - pre-clinical evidence Experimental Other treatment Sep/23/2022
Exosomal vaccine
Potential treatment - pre-clinical evidence Experimental Vaccine Jul/29/2022
Sotrovimab
Emergency use authorization Experimental Antiviral Jul/14/2022
EXO-CD24
Potential treatment - clinical evidence Experimental Other treatment Jul/13/2022
Nirmatrelvir
Emergency use authorization Experimental Antiviral Jun/23/2022
Molnupiravir
Emergency use authorization Experimental Antiviral Jun/23/2022
Bamlanivimab
Potential treatment - clinical evidence Experimental Antiviral Jun/23/2022
Etesevimab
Potential treatment - clinical evidence Experimental Antiviral Jun/23/2022
S309
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/22/2022
Ad26.COV2.S
Emergency use authorization Experimental Vaccine Jun/22/2022
BNT162b2
Approved by FDA Experimental Vaccine Jun/22/2022
mRNA-1273
Emergency use authorization Experimental Vaccine Jun/22/2022
Cilgavimab
Emergency use authorization Experimental Antiviral Jun/18/2022
Tixagevimab
Emergency use authorization Experimental Antiviral Jun/18/2022